Products for Research Use Only
RegisterLogin

Pitavastatin (Calcium)

CAT: 0804-HY-B0144-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0144-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects[1][2][3][8].
CAS Number
147526-32-7
Product Name Alternative
NK-104 (hemicalcium) ; Pitavastatin (hemicalcium)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; HMG-CoA Reductase (HMGCR) ; Mitophagy
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer; Metabolic Disease; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/pitavastatin-calcium.html
Purity
99.89
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C([O-])C[C@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4CC4.[0.5Ca2+]
Molecular Formula
C25H23FNO4.1/2Ca
Molecular Weight
440.49
Precautions
H302, H315, H319, H335
References & Citations
[1]Mukhtar RY, et al. Pitavastatin. Int J Clin Pract. 2005 Feb;59 (2) :239-52.|[2]Kajinami K, et al. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003 Fall;21 (3) :199-215.|[3]Tajiri K, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013 Oct;27 (5) :413-24.|[4]Hamano T, et al. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging. 2012 Oct;33 (10) :2306-20.|[5]de Wolf E, et al.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.Sci Rep. 2017 Jul 14;7 (1) :5410.|[6]Demir B, et al. The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture. Cardiovasc Ther. 2019 May 2;2019:2549432.|[7]Hayashi T, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis. 2004 Oct;176 (2) :255-63.|[8]Sahebkar A, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021 Nov;84:101127.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Acta Biochim Biophys Sin (Shanghai) . 2024 Apr 25;56 (4) :621-633.|Antioxidants (Basel) . 2024 May 29;13 (6) :667.|Bioorg Chem. 2024 Jun:147:107369.|Research Square Preprint. 2024 Apr 9.|Sci Data. 2024 Sep 19;11 (1) :1024.|Acta Biochim Biophys Sin (Shanghai) . 2024 Apr 25;56 (4) :621-633.|Acta Pharm Sin B. 2020 May;10 (5) :850-860.|Biochem Pharmacol. 2019 Nov:169:113612.|bioRxiv. 2024 June 11.|Braz J Med Biol Res. 2025 Aug 22:58:e14540.|J Hepatol. 2021 Aug;75 (2) :363-376.|Proteomics. 2023 Aug;23 (16) :e2300041.

Related Products

CatalogName
HY-B0144A-01Pitavastatin
HY-B0144AS-01Pitavastatin-d4
HY-108744Pitavastatin (magnesium)
HY-B0144AR-01Pitavastatin (Standard)
HY-125643-01Pitavastatin lactone
HY-B0144BPitavastatin (sodium)
HY-21315-01Pitavastatin impurity 12
HY-165668SPitavastatin lactone-d4
HY-B0144AS1Pitavastatin-d5 (sodium)
HY-B0144BS-01Pitavastatin-d4 (sodium)

Alternative Products

CatalogName
T2534-01Pitavastatin calcium

Popular Products